Clinical Trial Update: Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update examining peripheral body fat distribution after switching from zidovudine and lamivudine to Truvada in HIV-1 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Lamivudine (lamivudine)
• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)
• Zidovudine (Zidovudine)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 | Phase 4 | Status: COMPLETED | Results posted: 2009-05-20